AstraZeneca and Bristol Myers Squibb Deny Merger Rumors

AstraZeneca AZN and Bristol Myers Squibb BMY are denying they ever held merger talks, reversing days of speculation after a Financial Times report suggested the two had discussed a combination worth close to $400 billion [doc1 | doc2 | doc3]. A senior source close to the matter told Reuters there is no deal and never was one, and that no discussions are ongoing between the companies.

The reversal matters because a tie-up of that size would have created one of the largest pharmaceutical companies in the world, and the two firms have significant overlap in oncology that would likely have drawn heavy antitrust scrutiny. Neither company has offered an on-record comment confirming or elaborating on the denial.

The rumor and denial produced sharp, opposite stock swings: the initial merger report drove AstraZeneca shares down roughly 9%, while the denial helped the stock recover about 6%; Bristol Myers Squibb fell around 2.6% on the denial. The whiplash shows how sensitive both stocks are to M&A headlines given the size of the rumored deal.

With the denial now on record, investors are likely to shift focus back to each company's standalone pipeline and earnings trajectory rather than deal speculation, though how each company's oncology strategy evolves could determine whether the rumor resurfaces.

Related Stocks

• AZN
• BMY